Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

MIGRAINE

Potassium channel openers — novel triggers of aura and migraine

Nature Reviews Neurology volume 17, pages 397–398 (2021)Cite this article

Subjects

Results of two recent studies by Messoud Ashina and colleagues demonstrate that infusion of two different potassium channel openers can trigger migraine in humans; one of the compounds also triggered aura in patients diagnosed with migraine with aura. The findings highlight the importance of human experimental models in migraine research.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ashina, M. Migraine. N. Engl. J. Med. 383, 1866–1876 (2020).

    Article  CAS  Google Scholar 

  2. Ashina, M., Hansen, J. M., Á Dunga, B. O. & Olesen, J. Human models of migraine - short-term pain for long-term gain. Nat. Rev. Neurol. 13, 713–724 (2017).

    Article  Google Scholar 

  3. Ashina, H. et al. CGRP in human models of primary headaches. Cephalalgia. 38, 353–360 (2018).

    Article  Google Scholar 

  4. Al-Karagholi, M. A. et al. Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine. Pain https://doi.org/10.1097/j.pain.0000000000002238 (2021).

    Article  Google Scholar 

  5. Al-Karagholi, M. A. et al. Opening of ATP sensitive potassium channels causes migraine attacks with aura. Brain https://doi.org/10.1093/brain/awab136 (2021).

    Article  PubMed  Google Scholar 

  6. Ashina, M. et al. Migraine and the trigeminovascular system-40 years and counting. Lancet Neurol. 18, 795–804 (2019).

    Article  Google Scholar 

  7. Charles, A. et al. Targeting calcium gene-related peptide: a new era in migraine therapy. Lancet 394, 1765–1774 (2019).

    Article  CAS  Google Scholar 

  8. Vila-Pueyo, M., Strother, L. C., Kefel, M., Goadsby, P. J. & Holland, P. R. Divergent influences of the locus coeruleus on migraine pathophysiology. Pain 160, 385–394 (2019).

    Article  Google Scholar 

  9. Ayata, C. et al. Spreading Depression, Spreading Depolarizations, and the Cerebral Vasculature. Physiol. Rev. 95, 953–993 (2015).

    Article  CAS  Google Scholar 

  10. Dussor, G. in Neurobiological Basis of Migraine (eds T. Dalkara and M.A. Moskowitz) 49–68 (Wiley-Blackwell, 2017).

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    Alan M. Rapoport

  2. Department of Neurology, Albert Einstein College of Medicine, New York City, NY, USA

    Richard B. Lipton

  3. Montefiore Medical Center, New York City, NY, USA

    Richard B. Lipton

Authors
  1. Alan M. Rapoport
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard B. Lipton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alan M. Rapoport.

Ethics declarations

Competing interests

A.M.R. serves as an advisor for AbbVie, Amgen, Biohaven, Cala Health, Novartis, Satsuma, Teva Pharmaceutical Industries, Theranica, Xoc and Zosano; he is on the speaker bureau of AbbVie, Amgen, Biohaven, Lundbeck and Teva Pharmaceutical Industries. R.B.L. receives research support from the NIH and FDA as well as the National Headache Foundation and the Marx Foundation. He also receives research support from Allergan/Abbvie, Amgen, Biohaven Holdings, Eli Lilly and Electrocore. He receives personal fees as a consultant or advisor from Allergan/Abbvie, Amgen, Biohaven Holdings, Dr. Reddy’s, GlaxoSmithKline, Grifols, Impel NeuroPharma, Lundbeck, Merck, Novartis and Teva Pharmaceuticals. He holds stock or options in Biohaven Holdings and CtrlM Health. In addition, he receives royalties for Wolff’s Headache 7th and 8th Edition.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rapoport, A.M., Lipton, R.B. Potassium channel openers — novel triggers of aura and migraine. Nat Rev Neurol 17, 397–398 (2021). https://doi.org/10.1038/s41582-021-00517-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-021-00517-5

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing